Table 7.
EGFR mutation, ALK and PD-L1 expression in NSCLC according to the patients’ gender and smoking status
| No. of patients (%) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| PD-L1 expression | ||||||||||
| EGFR mutation-positive | EGFR mutation-negative | P value | ALK-positive | ALK-negative | P value |
TPS < 1% (None) |
TPS 1% to 49% (Low) |
TPS ≥ 50% (High) |
P value | |
| Male (n = 115) | 31 (27.0%) | 84 (73.0%) | ||||||||
| Never smoker (n = 30) | 17 (56.7%) | 13 (43.3%) | < 0.0001 | 1 (3.3%) | 29 (96.7%) | 1.000 | 11 (36.7%) | 14 (46.7%) | 5 (16.7%) | 0.326** |
| Ever smoker (pack-years of smoking) (n = 75) | 14 (16.5%) | 71 (83.5%) | 2 (2.4%) | 83 (97.6%) | 29 (34.1%) | 33 (38.8%) | 23 (27.1%) | |||
| < 20 (Light smoker n = 16) | 6 (37.5%) | 10 (62.5%) | 0.039a | 1 (6.3%) | 15 (93.8%) | 0.254a | 8 (50.0%) | 7 (43.8%) | 1 (6.3%) | 0.015*** |
| 20–39 (Moderate smoker n = 21) | 3 (14.3%) | 18 (85.7%) | 1 (4.8%) | 20 (95.2%) | 6 (28.6%) | 11 (52.4%) | 4 (19.0%) | |||
| ≥ 40 (Heavy smoker n = 48) | 5 (10.4%) | 43 (89.6%) | 0 | 48 (100.0%) | 15 (31.3%) | 15 (31.3%) | 18 (37.5%) | |||
| Female (n = 76) | 50 (65.8%) | 26 (34.2%) | 5 (7.0%) | 66 (93.0%) | 32 (42.1%) | 34 (44.7%) | 10 (13.2%) | |||
| Never smoker (71) | 48 (67.6%) | 23 (32.4%) | 0.331 | 5 (7.0%) | 66 (93.0%) | 1.000 | 30 (42.3%) | 32 (45.1%) | 9 (12.7%) | 0.516** |
| Ever smoker (pack-years of smoking) (n = 5) | 2 (40.0%) | 3 (60.0%) | 0 | 5 (100.0%) | 2 (40.0%) | 2 (40.0%) | 1 (20.0%) | |||
| < 20 (Light smoker n = 0) | 0 | 0 | - | 0 | 0 | - | 0 | 0 | 0 | - |
| 20–39 (Moderate smoker n = 0) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||
| ≥ 40 (Heavy smoker n = 5) | 2 (40.0%) | 3 (60.0%) | 0 | 5 (100.0%) | 2 (40.0%) | 2 (40.0%) | 1 (20.0%) | |||
TPS = Tumor proportion score
aComparison between EGFR mutation-positivity or ALK-positivity in heavy smokers versus light and moderate smokers
**Comparison between high PD-L1 expression (TPS ≥ 50%) versus no (TPS < 1%) and low PD-L1 expression (TPS 1%-50%) in smokers versus never smokers
***Comparison between high PD-L1 expression (TPS ≥ 50%) versus no (TPS < 1%) and low PD-L1 expression (TPS 1%-50%) in heavy smokers versus light and moderate smokers